Experiences with
Tafinlar11 public posts
Want to take advantage of all our features? Just log in!
or
BRA/ Mek Treatment holiday flops in late stage melanoma trial
In the phase II study of over 200 patients, median progression-free survival (PFS) for those receiving intermittent dosing of dabrafenib (Tafinlar) and trametinib (Mekinist) was 5.5 months, as compared to 9.0 months for patients receiving continuous treatment (HR 1.36, 80% CI 1.10-1.66, P=0.063), reported
GREAT NEWS: HEALTH CANADA APPROVES FIRST ADJUVANT TREATMENT FOR MELANOMA TO PREVENT RELAPSE FOLLOWING SURGERY!
Health Canada has just approved the use of a combination therapy of Tafinlar® (dabrafenib) plus Mekinist® (trametinib) to prevent recurrence of melanoma following surgery in patients with a stage II or stage III diagnosis, also referred to as ‘adjuvant’ treatment.